Lower protein in infant formula is associated with lower weight up to age 2 y: a randomized clinical trial

Berthold Koletzko1, Rüdiger von Kries, Ricardo Closa

  • 1Dr von Hauner Children's Hospital, University of Munich Medical Centre, Munich, Germany. office.koletzko@med.uni-muenchen.de

Insights

Higher protein infant formula is linked to increased weight gain in the first two years, but does not affect length. Lower protein intake may reduce the risk of later obesity.

Area of Science:

  • Pediatric Nutrition
  • Human Growth and Development
  • Infant Formula Composition

Background:

  • Observational studies suggest a link between infant protein intake, rapid early weight gain, and later obesity.
  • Understanding the impact of protein content in infant formula on growth is crucial for long-term health outcomes.

Purpose of the Study:

  • To investigate if higher protein intake in infant formula promotes faster length and weight gain during the first two years of life.
  • To test the hypothesis that early protein consumption influences infant growth trajectories.

Main Methods:

  • A multicenter European study randomized 1138 healthy formula-fed infants to lower or higher protein formulas for the first year.
  • Growth parameters (weight, length, weight-for-length z scores) were assessed up to 24 months of age.
  • A cohort of 619 exclusively breastfed infants served as a reference group.

Main Results:

  • No significant differences in length were observed between the formula groups at any time point.
  • Infants receiving lower protein formula had a lower weight-for-length z score at 24 months compared to the higher protein group.
  • The weight-for-length z score in the lower protein group did not differ from the exclusively breastfed reference group.

Conclusions:

  • Higher protein content in infant formula is associated with increased weight gain in the first two years but does not impact length.
  • Reducing protein content in infant formula may potentially decrease the risk of overweight and obesity later in life.
  • This study provides evidence for optimizing infant formula composition to support healthy growth patterns.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...